TY - JOUR
T1 - Assessment of Endothelial Dysfunction With Flow-Mediated Dilatation in Myeloproliferative Disorders
AU - Yildiz, Abdulkerim
AU - Güryildirim, Melike
AU - Pepeler, Mehmet Sezgin
AU - Yazol, Merve
AU - Oktar, Suna Özhan
AU - Acar, Kadir
N1 - Publisher Copyright:
© The Author(s) 2018.
PY - 2018/10/1
Y1 - 2018/10/1
N2 - Background: Thrombosis is the most important cardiovascular complication of classical myeloproliferative disorders (MPDs). Endothelial dysfunction (ED) is known to play a major role in the mechanism of thrombophilia in MPDs. Methods: Endothelial dysfunction and its associations with other parameters were investigated. A total of 18 patients with polycythemia vera (PV), 24 with essential thrombocytosis (ET), 7 with primary myelofibrosis (PMF), and 30 healthy patients as a control group were included in the study. To assess the ED, flow-mediated dilatation (FMD) measurements were used. Results: The FMD (%) result showing ED was determined as 9.9 (0.0-21.6) in the patients with PV, 7.3 (0.0-30.5) in patients with ET, 7.5 (0.0-18.0) in patients with PMF, and 13.9 (6.2-26.7) in the control group. The FMD (%) was markedly impaired in all patients with MPD compared to the control patients (7.8 [0.0-30.5] vs 13.9 [6.15-26.8], P =.02). According to the disease subtypes, FMD (%) was significantly lower in the ET group than in the control group (P =.01). Conclusion: Endothelial function was assessed in patients with MPD having FMD and was determined to demonstrate ED. Lower FMD was associated with older age, leukocytosis, thrombocytosis, and thrombosis history.
AB - Background: Thrombosis is the most important cardiovascular complication of classical myeloproliferative disorders (MPDs). Endothelial dysfunction (ED) is known to play a major role in the mechanism of thrombophilia in MPDs. Methods: Endothelial dysfunction and its associations with other parameters were investigated. A total of 18 patients with polycythemia vera (PV), 24 with essential thrombocytosis (ET), 7 with primary myelofibrosis (PMF), and 30 healthy patients as a control group were included in the study. To assess the ED, flow-mediated dilatation (FMD) measurements were used. Results: The FMD (%) result showing ED was determined as 9.9 (0.0-21.6) in the patients with PV, 7.3 (0.0-30.5) in patients with ET, 7.5 (0.0-18.0) in patients with PMF, and 13.9 (6.2-26.7) in the control group. The FMD (%) was markedly impaired in all patients with MPD compared to the control patients (7.8 [0.0-30.5] vs 13.9 [6.15-26.8], P =.02). According to the disease subtypes, FMD (%) was significantly lower in the ET group than in the control group (P =.01). Conclusion: Endothelial function was assessed in patients with MPD having FMD and was determined to demonstrate ED. Lower FMD was associated with older age, leukocytosis, thrombocytosis, and thrombosis history.
KW - endothelial dysfunction
KW - flow-mediated dilatation
KW - myeloproliferative disorders
KW - risk factors
KW - thrombosis
UR - http://www.scopus.com/inward/record.url?scp=85046729797&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85046729797&partnerID=8YFLogxK
U2 - 10.1177/1076029618766260
DO - 10.1177/1076029618766260
M3 - Article
C2 - 29683036
AN - SCOPUS:85046729797
SN - 1076-0296
VL - 24
SP - 1102
EP - 1108
JO - Clinical and Applied Thrombosis/Hemostasis
JF - Clinical and Applied Thrombosis/Hemostasis
IS - 7
ER -